NASDAQ:AADI Aadi Bioscience (AADI) Stock Price, News & Analysis → Biden replacement revealed? (From Paradigm Press) (Ad) Free AADI Stock Alerts $1.74 -0.03 (-1.69%) (As of 06/7/2024 08:51 PM ET) Add Compare Share Share Today's Range$1.71▼$1.7850-Day Range$1.68▼$2.3152-Week Range$1.55▼$8.49Volume147,900 shsAverage Volume309,472 shsMarket Capitalization$42.72 millionP/E RatioN/ADividend YieldN/APrice Target$20.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Aadi Bioscience alerts: Email Address Aadi Bioscience MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside1,078.2% Upside$20.50 Price TargetShort InterestHealthy5.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$118,253 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.54) to ($2.86) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.63 out of 5 starsMedical Sector391st out of 903 stocksPharmaceutical Preparations Industry181st out of 426 stocks 3.3 Analyst's Opinion Consensus RatingAadi Bioscience has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageAadi Bioscience has only been the subject of 1 research reports in the past 90 days.Read more about Aadi Bioscience's stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted5.54% of the float of Aadi Bioscience has been sold short.Short Interest Ratio / Days to CoverAadi Bioscience has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aadi Bioscience has recently decreased by 14.69%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAadi Bioscience does not currently pay a dividend.Dividend GrowthAadi Bioscience does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AADI. Previous Next N/A News and Social Media Coverage Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aadi Bioscience insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $118,253.00 in company stock.Percentage Held by Insiders37.30% of the stock of Aadi Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.08% of the stock of Aadi Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aadi Bioscience's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aadi Bioscience are expected to decrease in the coming year, from ($2.54) to ($2.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aadi Bioscience is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aadi Bioscience is -0.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAadi Bioscience has a P/B Ratio of 0.41. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aadi Bioscience's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyHow Biden has already won 2024Obama’s Forever Term [Exposed] or Obama Biden has already won 2024 Exposed: the shocking election plot that will forever enshrine Obama’s destructive, Marxist vision for America… A plot that could hand him and his allies near-total control over the government, your way of life, and your future.Click here to watch this now before it’s too late. About Aadi Bioscience Stock (NASDAQ:AADI)Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.Read More AADI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AADI Stock News HeadlinesMay 31, 2024 | americanbankingnews.comAadi Bioscience, Inc. (NASDAQ:AADI) Sees Significant Drop in Short InterestMay 29, 2024 | prnewswire.comAadi Bioscience to Participate in the Jefferies Healthcare ConferenceMay 23, 2024 | prnewswire.comAadi Bioscience Presents New Nonclinical Data Demonstrating Preferential Tumor Uptake of nab-Sirolimus at the American Society of Clinical Oncology (ASCO) Annual MeetingMay 15, 2024 | marketwatch.comArcutis Biotherapeutics Shares Climb 24% on 1Q Revenue SurgeMay 11, 2024 | finance.yahoo.comAadi Bioscience, Inc. (NASDAQ:AADI) Analysts Are Cutting Their Estimates: Here's What You Need To KnowMay 10, 2024 | finance.yahoo.comAnalysts Just Made A Major Revision To Their Aadi Bioscience, Inc. (NASDAQ:AADI) Revenue ForecastsMay 9, 2024 | washingtonpost.comArlo Technologies: Q1 Earnings SnapshotMay 9, 2024 | insidermonkey.comAadi Bioscience, Inc. (NASDAQ:AADI) Q1 2024 Earnings Call TranscriptMay 9, 2024 | finance.yahoo.comAadi Bioscience First Quarter 2024 Earnings: US$0.68 loss per share (vs US$0.57 loss in 1Q 2023)May 9, 2024 | finance.yahoo.comAadi Bioscience Inc (AADI) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges ...May 8, 2024 | investorplace.comAADI Stock Earnings: Aadi Bioscience Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | prnewswire.comAadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate UpdateMay 7, 2024 | markets.businessinsider.comAadi Bioscience is about to announce its earnings — here's what to expectMay 1, 2024 | prnewswire.comAadi Bioscience to Report First Quarter 2024 Results and Corporate UpdateApril 29, 2024 | finance.yahoo.comBiodexa gains license for polyposis asset as stock more than doublesApril 26, 2024 | msn.comCongress releases candidate list for three Lok Sabha, 11 Assembly seats in Andhra PradeshApril 9, 2024 | finance.yahoo.comAadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingApril 9, 2024 | prnewswire.comAadi Bioscience to Present New Non-clinical Data Highlighting Combinability of nab-Sirolimus at the American Association for Cancer Research (AACR) Annual MeetingMarch 17, 2024 | prnewswire.comAadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO)March 16, 2024 | uk.investing.comEarnings call: Aadi Bioscience sees 60% growth in FYARRO salesMarch 16, 2024 | finance.yahoo.comAADI Apr 2024 10.000 callMarch 16, 2024 | finance.yahoo.comAADI Oct 2024 2.500 putMarch 16, 2024 | finance.yahoo.comAADI Jul 2024 2.500 putMarch 15, 2024 | seekingalpha.comAadi Bioscience, Inc. (AADI) Q4 2023 Earnings Call TranscriptMarch 15, 2024 | finance.yahoo.comAadi Bioscience, Inc. (NASDAQ:AADI) Q4 2023 Earnings Call TranscriptSee More Headlines Receive AADI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aadi Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/09/2024Next Earnings (Estimated)8/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AADI CUSIPN/A CIK1422142 Webaadibio.com Phone(424) 473-8055FaxN/AEmployees75Year FoundedN/APrice Target and Rating Average Stock Price Target$20.50 High Stock Price Target$36.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,078.2%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($2.55) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,760,000.00 Net Margins-288.72% Pretax Margin-288.72% Return on Equity-61.83% Return on Assets-51.52% Debt Debt-to-Equity RatioN/A Current Ratio5.16 Quick Ratio4.86 Sales & Book Value Annual Sales$24.35 million Price / Sales1.75 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.41Miscellaneous Outstanding Shares24,550,000Free Float15,395,000Market Cap$42.72 million OptionableOptionable Beta0.66 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Neil P. Desai Ph.D. (Age 59)Founder & Executive Chairman Comp: $710.35kMr. David J. Lennon Ph.D. (Age 53)President, CEO & Director Comp: $277.75kMr. Scott M. Giacobello CPA (Age 54)CFO, Treasurer, Investor Relations & Corporate Communications Comp: $643.23kDr. Loretta M. Itri F.A.C.P. (Age 74)M.D., Chief Medical Officer Comp: $617.45kMr. Stephen M. Rodin J.D. (Age 48)Senior VP of Legal & General Counsel Mr. Raymond G. Steitz (Age 65)Senior VP of Human Resources & Chief Human Resources Officer Mr. Bryan Ball (Age 54)Chief Quality Officer & Senior VP of Manufacturing Operations More ExecutivesKey CompetitorsAkoya BiosciencesNASDAQ:AKYAAllakosNASDAQ:ALLKPuma BiotechnologyNASDAQ:PBYITelomir PharmaceuticalsNASDAQ:TELOCapricor TherapeuticsNASDAQ:CAPRView All CompetitorsInsiders & InstitutionsMarquette Asset Management LLCBought 57,807 shares on 5/7/2024Ownership: 0.235%Neil DesaiSold 40,000 sharesTotal: $77,200.00 ($1.93/share)Neil DesaiSold 17,772 sharesTotal: $41,053.32 ($2.31/share)Neil DesaiSold 14,964 sharesTotal: $31,424.40 ($2.10/share)Neil DesaiSold 27,036 sharesTotal: $53,260.92 ($1.97/share)View All Insider TransactionsView All Institutional Transactions AADI Stock Analysis - Frequently Asked Questions Should I buy or sell Aadi Bioscience stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aadi Bioscience in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" AADI shares. View AADI analyst ratings or view top-rated stocks. What is Aadi Bioscience's stock price target for 2024? 2 brokerages have issued twelve-month price targets for Aadi Bioscience's shares. Their AADI share price targets range from $5.00 to $36.00. On average, they predict the company's share price to reach $20.50 in the next year. This suggests a possible upside of 1,078.2% from the stock's current price. View analysts price targets for AADI or view top-rated stocks among Wall Street analysts. How have AADI shares performed in 2024? Aadi Bioscience's stock was trading at $2.02 on January 1st, 2024. Since then, AADI stock has decreased by 13.9% and is now trading at $1.74. View the best growth stocks for 2024 here. Are investors shorting Aadi Bioscience? Aadi Bioscience saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 964,000 shares, a decrease of 14.7% from the April 30th total of 1,130,000 shares. Based on an average daily volume of 331,000 shares, the days-to-cover ratio is currently 2.9 days. Approximately 5.5% of the company's stock are short sold. View Aadi Bioscience's Short Interest. When is Aadi Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024. View our AADI earnings forecast. How were Aadi Bioscience's earnings last quarter? Aadi Bioscience, Inc. (NASDAQ:AADI) released its quarterly earnings data on Wednesday, May, 8th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by $0.02. The company earned $5.35 million during the quarter, compared to analysts' expectations of $6.41 million. Aadi Bioscience had a negative net margin of 288.72% and a negative trailing twelve-month return on equity of 61.83%. When did Aadi Bioscience's stock split? Aadi Bioscience shares reverse split on the morning of Friday, August 27th 2021. The 1-15 reverse split was announced on Thursday, August 26th 2021. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, August 25th 2021. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split. Who are Aadi Bioscience's major shareholders? Aadi Bioscience's stock is owned by many different institutional and retail investors. Top institutional shareholders include Marquette Asset Management LLC (0.24%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Caley Castelein and Neil Desai. View institutional ownership trends. How do I buy shares of Aadi Bioscience? Shares of AADI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AADI) was last updated on 6/10/2024 by MarketBeat.com Staff From Our PartnersWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredIt's time to ween off Chinese lithium!As the lithium rush continues, this small-cap NASDAQ-traded company may be one of the brightest and most promi...Smallcaps Daily | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | SponsoredThe Only Energy Play You Should Be Looking AtOpen AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro | SponsoredYou won't believe what Citigroup just did to it's depositorsThe FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st...American Alternative | SponsoredRSVP: Charles Payne’s Cash Flow WorkshopDid you know you could "cash flow" the stocks in your portfolio? Without selling a single share of stock? ...Unstoppable Prosperity | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aadi Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aadi Bioscience With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.